



3Q & 9M 2024 FINANCIAL RESULTS

November 11, 2024



This document has been prepared by Antares Vision S.p.A for use during meetings with investors and financial analysts and is solely for information purposes. The information set out here in has not been verified by an independent audit company.

Neither the Company nor any of its subsidiaries, affiliates, branches, representative offices (the "Group"), as well as any of their directors, officers, employees, advisers or agents (the "Group Representatives") accepts any responsibility for/or makes any representation or warranty, express or implied, as to the accuracy, timeliness or completeness of the information set out herein or any other related information regarding the Group, whether written, oral or in visual or electronic form, transmitted or made available.

This document may contain forward-looking statements about the Company and/or the Group based on current expectations and opinions developed by the Company, as well as based on current plans, estimates, projections and projects of the Group. These forward-looking statements are subject to significant risks and uncertainties (many of which are outside the control of the Company and/or the Group) which could cause a material difference between forward-looking information and actual future results.

The information set out in this document is provided as of the date indicated here in. Except as required by applicable laws and regulations, the Company assumes no obligation to provide updates of any of the aforesaid forward-looking statements.

Under no circumstances shall the Group and/or any of the Group Representatives be held liable (for negligence or otherwise) for any loss or damage howsoever arising from any use of this document or its contents or otherwise in connection with the document or the aforesaid forward-looking statements. This document does not constitute an offer to sell or a solicitation to buy or subscribe to Company shares and neither this entire document or a portion of it may constitute a recommendation to affect any transaction or to conclude any legal act of any kind whatsoever.

This document may not be reproduced or distributed, in whole or in part, by any person other than the Company. By viewing and/or accepting a copy of this document, you agree to be bound by the foregoing limitations.



9M 2024 RESULTS




9M 2024 RESULTS CONFIRM IMPROVING MARGINALITY TREND RECORDED IN 1H 2024, MITIGATING SOFT SALES PERFORMANCE





9M 2024 REVENUES EQUAL TO €127.9M, -5.6% Y/Y ON L4L BASIS





CGU & BU New Group's structure is based on 4 CGUs


(LifeScience & Cosmetics, FMCG, SCT, Other) and 5 Business Units (LifeScience & Cosmetics, FMCG, SCT, Services, Other) The **Life Science & Cosmetics** CGU registered a 9M 2024 slowdown (-6%), although confirmed as the most relevant Unit in terms of impact on total sales (43%)

In 3Q 2024, the **FMCG** CGU recorded a turnaround of +1% Vs. a double-digit decrease posted in 1H 2024


The **Supply Chain Transparency** CGU, which includes Level 4 and Level 5 Groups' software solutions, was stable in 9M24

Focusing on the Business Unit organization, **Recurring Revenues** (Services + SCT) posted a combined growth of 5% and accounted for 46% of total revenues vs. 39% in 9M 23












Geographic Areas Italy confirmed as the fastest growing area in 9M 2024 **Europe, including Italy,** confirmed as the Group's most important region, with revenues accounting for 52% of sales vs. 45% in 9M 2023

Italy's growth is mainly driven by Track & Trace (change in Pharma legislation expected by 1H 2025), Inspection System and Digital Healthcare

Americas, the second most important region, recorded a 22% decline, impacted by a slowdown registered both in FMCG and LS markets; currently at 37% of Group's sales vs. 43% in 9M 2023








STRATEGIC PROJECTS







STRONG BUSINESS UNITS' REORGANIZATION, FROM OPERATION TO PRODUCT DESIGN AND GEOGRAPHICAL MARKETS FOCUS. GOALS:



Standardize the product portfolio introducing the concept of modularity



Optimize the use of critical components (cameras, embedded pcs, automation, etc.) and mechanical parts based on a more accurate budgeting process and shorter supplying



Reduce the **complexity** to improve the usability of the machines





CLOSING REMARKS



Thanks to the **new organization** and to the numerous efficiency projects implemented, the Group will be able to achieve targets set for FY 2024:



Revenues growth in the range of +4/6% on L4L basis: starting point FY 2023 revenue base of €204M, mainly due to deconsolidation of the Russian business

Adjusted EBITDA Margin in the higher part of the 11.5/14% range



2

Net Debt/EBITDA in the lower part of 4.1/3.3x ratio, thanks to a robust operating cash generation





Alessandro Baj Badino

Head of Investor Relations & Corporate Communication

+39 335 122 30 89

Alessandro.bajbadino@antaresvision.com

Davide Antonioli

Investor Relator

😋 +39 339 812 44 46

Davide.antonioli@antaresvision.com